What is Putney?
Putney operates within the pharmaceutical industry, specializing in the development and provision of high-quality, affordable generic medicines for pets. The company's mission is to empower veterinarians with reliable access to cost-effective drug options, thereby enabling them to deliver optimal care and support pet owners in adhering to treatment recommendations. Putney's strategic focus on research and development is informed by insights from companion animal veterinarians and industry partners, aiming to create the next generation of generic veterinary products.
How much funding has Putney raised?
Putney has raised a total of $49.3M across 5 funding rounds:
Series A
$2.5M
Series B
$6.7M
Series C
$21M
Debt
$3M
Private Equity
$16.1M
Series A (2007): $2.5M, investors not publicly disclosed
Series B (2009): $6.7M, investors not publicly disclosed
Series C (2011): $21M supported by NewSpring Capital and Safeguard Scientifics
Debt (2014): $3M featuring NewSpring Health Capital
Private Equity (2014): $16.1M, investors not publicly disclosed
Key Investors in Putney
NewSpring Health Capital
NewSpring Health Capital is a venture capital firm that partners with companies in dynamic industries to catalyze new growth. They focus on identifying opportunities and building relationships through their network of industry leaders, particularly in the healthcare sector.
Safeguard Scientifics
Safeguard Scientifics is a venture capital and private equity firm established in 1953. Based in Pennsylvania, it provides capital and expertise to technology-driven businesses, with a notable focus on the healthcare sector.
What's next for Putney?
With a history of consistent investment, including Series A, B, and C rounds, alongside debt financing and private equity, Putney is positioned for continued growth and innovation in the generic veterinary pharmaceutical market. The recent major strategic investment signals a strong confidence in the company's business model and its capacity to expand its product pipeline and market reach. This backing will likely fuel further research into novel generic formulations and enhance supply chain capabilities, reinforcing Putney's commitment to affordability and accessibility in veterinary care.
See full Putney company page
